Loading...

BioNexus Gene Lab Corp.

BGLCNASDAQ
Healthcare
Medical - Diagnostics & Research
$2.22
$-0.01(-0.45%)
U.S. Market opens in 23h 0m

BioNexus Gene Lab Corp. (BGLC) Stock Forecast & Price Predictions

Get the latest BioNexus Gene Lab Corp. (BGLC) stock forecast across short-term and long-term horizons. Meyka AI generates price predictions using advanced models trained on historical data. These forecasts are not investment advice but directional insights to help investors and traders plan strategies.

Model Information

The Forecast Prediction Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full Disclaimer

Monthly Forecast

Predicted Price$4.88
Change↑ $2.66 (119.82%)

Quarterly Forecast

Predicted Price$4.13
Change↑ $1.91 (86.04%)

Yearly Forecast

Predicted Price$7.37
Change↑ $5.15 (231.92%)

3 Years Forecast

Predicted Price$12.38
Change↑ $10.16 (457.71%)

5 Years Forecast

Predicted Price$17.36
Change↑ $15.14 (682.04%)

7 Years Forecast

Predicted Price$21.74
Change↑ $19.52 (879.28%)

BioNexus Gene Lab Corp. Stock Forecast Summary

BioNexus Gene Lab Corp. (BGLC) stock is currently priced at $2.22. Based on Meyka AI predictions, the short-term outlook is bullish, with momentum pointing higher. The 1-month projection suggests a move toward $4.88.

In the long term, BGLC shows a bullish trend. The 2027 forecast points to $7.37 (231.92% change), while the 2031 forecast suggests $17.36 (682.04% change). Looking 7 years ahead, projections estimate the stock could trade near $21.74, a 879.28% change from today’s price.

Overall Sentiment

Bullish

Short-Term Outlook

Bullish

Long-Term Outlook

Bullish

This mix indicates that BioNexus Gene Lab Corp. stock is expected to rise steadily over the coming years.

Investment Calculator

Estimate your potential returns on BGLC using our advanced Investment Calculator with AI-driven price forecasts. Enter your investment amount and select a target date to view expected results, including estimated profit, loss, and ROI performance.

Based on your investment of $1,000.00 in BioNexus Gene Lab Corp. and holding until April 26th, 2027, you could face a potential +$2,319.17 profit, reflecting a +231.9% ROI over the next 365 days. These projections help you better understand short-term market movements.

$

$Shares Bought

450.4505

@ $2.22/share

~Forecast Price

$7.37

1-year AI forecast

$Est. Portfolio Value

$3,319.17

+$2,319.17 profit

%ROI

+231.9%

return on investment

BioNexus Gene Lab Corp. yearly Price Forecast Chart

Explore the yearly forecast chart for BGLC, which maps expected price movement, support levels, and resistance targets. The dropdown lets you view forecasts across multiple horizons, from short-term daily trends to 7-year projections, helping investors evaluate BioNexus Gene Lab Corp. over different timeframes.

No forecast data available

No prediction data found for this time period.

empty-state-iconForecasting data is not available for BGLCForecasting details for BGLC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

BioNexus Gene Lab Corp. Stock Forecast 2026

The forecast for BioNexus Gene Lab Corp. (BGLC) in 2026 suggests a price of $7.37, representing a 231.92% move from today’s price.

Average Target: $7.37

Market Outlook: bullish based on current trend indicators.

Key Drivers in 2026:
  • Earnings growth projections.
  • Competitive performance in the Healthcare.
  • Macroeconomic factors such as interest rates and inflation.

BioNexus Gene Lab Corp. Stock Forecast 2030

By 2030, Meyka AI projects BGLC could trade near $17.36, showing a potential 682.04% compared to current levels.

Average Target: $17.36

Market Outlook: bullish.

What could influence the 2030 forecast:
  • Technological innovation and product cycles.
  • Expansion into global markets.
  • Long-term investor sentiment toward BioNexus Gene Lab Corp..

BioNexus Gene Lab Corp. 7-Year Stock Forecast (20322033)

Looking 7 years ahead, the long-term forecast for BGLC points to a price around $21.74, which is a projected 879.28% move from today’s level.

Average Target: $21.74

Outlook: bullish, depending on macroeconomic conditions and sector growth.

Long-Term Drivers:
  • Global economic expansion or contraction.
  • Regulatory and policy environment.
  • BioNexus Gene Lab Corp.’s ability to maintain market leadership.

Frequently Asked Questions